Yahoo Finance • 4 days ago
NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton... Full story
Yahoo Finance • 9 days ago
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton... Full story
Yahoo Finance • 9 days ago
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several nota... Full story
Yahoo Finance • 13 days ago
In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The company reported a patient death followi... Full story
Yahoo Finance • 13 days ago
Sarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold. Continue Reading View Comments... Full story
Yahoo Finance • 18 days ago
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other best mid cap biotech stocks to buy. Is the... Full story
Yahoo Finance • 28 days ago
We recently published a list of Pulse of the Market: Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other Wednesday’s top performers. The stock m... Full story
Yahoo Finance • 29 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRP... Full story
Yahoo Finance • 29 days ago
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges On Tuesday, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-r... Full story
Yahoo Finance • 2 months ago
Participants Vincent Anzalone; Investor Relations; Arrowhead Pharmaceuticals Inc Christopher Anzalone; President, Chief Executive Officer, Director; Arrowhead Pharmaceuticals Inc Bruce Given; Chief Operating Officer; Arrowhead Pharmaceu... Full story
Yahoo Finance • 2 months ago
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring. Two healthcare stocks that may... Full story
Yahoo Finance • 2 months ago
We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host... Full story
Yahoo Finance • 3 months ago
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc. (SRPT)'s share was trading at... Full story
Yahoo Finance • 7 months ago
The market is up 1.2% over the last week and has risen 30% over the past 12 months, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high-growth tech stocks like TeraWulf can be crucial for investo... Full story
Yahoo Finance • 8 months ago
CAMBRIDGE, Mass., August 30, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Mor... Full story
Yahoo Finance • 9 months ago
This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes During earnings season, big banks are often among the first companies to unveil their quarterly financial results. But rather t... Full story
Yahoo Finance • 11 months ago
We recently compiled the list of the 10 Best Fast Growth Stocks To Buy according to the hedge funds using the latest sentiment data. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands agai... Full story
Yahoo Finance • 11 months ago
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) just released its quarterly report and things are looking bullish. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 10% highe... Full story
Yahoo Finance • last year
In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out... Full story
Yahoo Finance • last year
In this article, we will take a detailed look at Billionaire Ray Dalio and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ray Dalio and Insiders Love These 5 Stocks. Investors are on tente... Full story